English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Aims/Introduction  Compared with glargine 100 U/ mL  (Gla100), glargine 300 U/ mL  (Gla300) and degludec (Deg) – the ultralong‐acting insulins – reportedly have more stable effects and reduce the risk of hypoglycemia. Currently, they are considered to be the most useful basal insulins. The present study aimed to compare the efficacy and safety of Gla300 and Deg on glycemic control using continuous glucose monitoring.    Materials and Methods  In this single‐center, open‐label, parallel‐group, two‐period, cross‐over study, 30 patients with type 2 diabetes were randomized to once‐daily Gla300 followed by Deg with the same units ( n  = 15) or vice versa ( n  = 15). The primary end‐points of this study were the mean percentage of time within the target glucose range of 70–180 mg/ dL  as efficacy and hypoglycemia of <70 mg/ dL  as safety indicators, as measured using continuous glucose monitoring during each treatment period.    Results  The mean percentage of time within the target glucose range was not different between Gla300 and Deg (77.8 ± 19.2 vs 76.9 ± 18.3%,  P  = 0.848). However, the mean percentage of time of hypoglycemia with Gla300 was significantly lower than that of Deg (1.3 ± 2.7 vs 5.5 ± 6.4%,  P  = 0.002). In the secondary safety end‐points, the mean percentage of time of severe hypoglycemia (<54 mg/ dL ) or nocturnal hypoglycemia with Gla300 was also significantly lower than that of Deg.    Conclusions  The present study showed the comparable efficacy of Gla300 and Deg on glycemic control; however, the risk of hypoglycemia was markedly lower for Gla300 than for Deg.

journal of diabetes investigation

Efficacy and safety of insulin glargine 300 U/ mL  vs insulin degludec in patients with type 2 diabetes: A randomized, open‐label, cross‐over study using continuous glucose monitoring profiles